Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

摘要: Daptomycin is a novel cyclic lipopeptide antibiotic that provides rapid bactericidal activity against gram-positive pathogens in vitro, including methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. vancomycin-resistant penicillin-resistant Streptococcus pneumoniae, and ampicillin- enterococci. The United States Food Drug Administration recently approved daptomycin for treatment of complicated skin skin-structure infections. Its efficacy the more-serious infections (e.g., staphylococcal bacteremia) under investigation. As an intravenous agent administered once per day, it offers convenient regimen therapy continued after discharge, with side effect profile appears minimal manageable. Spontaneous acquisition resistance vitro rare, hopefully this characteristic will extrapolate into clinical setting. activity, low potential resistance, promising safety associated make useful addition to our growing armamentarium antibiotics active pathogens.